S

SpringWorks Therapeutics
D

SWTX

46.790
USD
-0.07
(-0.15%)
Market Closed
Volume
595,559
EPS
-3
Div Yield
-
P/E
-14
Market Cap
3,525,575,592
Related Instruments
B
BEAM
0.330
(1.98%)
16.980 USD
C
CLSD
0.00900
(1.14%)
0.79900 USD
C
CRNX
-0.330
(-1.07%)
30.520 USD
C
CRSP
1.240
(2.87%)
44.430 USD
E
EDIT
0.21000
(9.84%)
2.34500 USD
M
MGTX
0.17600
(2.78%)
6.49600 USD
N
NTLA
0.01500
(0.16%)
9.60000 USD
R
RGNX
-0.09000
(-1.04%)
8.55000 USD
S
SGMO
0.00140
(0.29%)
0.48400 USD
VRTX
VRTX
6.60
(1.49%)
448.61 USD
More
News

Title: SpringWorks Therapeutics

Sector: Healthcare
Industry: Biotechnology
SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.